Parkman Healthcare Partners’s Regenxbio RGNX Stock Holding History

Parkman Healthcare Partners’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-85,000	Closed	-$3.48M	–	72
2019 Q4	$3.48M	Buy	+85,000	New	+$3.36M	1.01%	33

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Parkman Healthcare Partners's RGNX Position: Q1 2020 in Review

Parkman Healthcare Partners sold out of Regenxbio (RGNX) in Q1 2020, closing a stake of 85,000 shares — an estimated $3.48M sold.

Parkman Healthcare Partners first reported a position in RGNX in Q4 2019 and held it in 1 quarter. The position peaked at $3.48M in Q4 2019. 170 funds tracked by Wall St. Rank hold RGNX as of Q1 2020.

Parkman Healthcare Partners reported no remaining Regenxbio position as of Q1 2020 after selling out during the quarter.
Parkman Healthcare Partners sold 85,000 Regenxbio shares in Q1 2020, an estimated $3.48M.
Parkman Healthcare Partners first reported a position in Regenxbio in Q4 2019 and held it in 1 quarter.
Parkman Healthcare Partners's Regenxbio position peaked at $3.48M in Q4 2019.
170 funds tracked by Wall St. Rank held Regenxbio as of Q1 2020.

Based on Parkman Healthcare Partners's 13F filing for Q1 2020, filed 15 May 2020.